FingerMotion (NASDAQ:FNGR) reported $4.86 million in sales this quarter.
Neuron23 and QIAGEN Announced Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug; Terms Not Disclosed
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease.
